Organogenesis offers a specialized portfolio of advanced regenerative medicine products designed primarily for the acute wound care, chronic ulcer management, and surgical markets. Its flagship commercial offerings include bio-active skin substitutes, cellular and tissue-based products derived from human donor materials, and amniotic membrane suspensions. These advanced medical therapies are engineered specifically to assist clinicians in healing complex, treatment-resistant chronic wounds such as diabetic foot ulcers and severe venous leg ulcers.